http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
FASHION THERAPY RESEARCH TRENDS AND PROPOSAL FOR ENHANCING HAPPINESS
Sae-eun Lee,Yuri Lee,Jisoo Ha,Joeun Lee 글로벌지식마케팅경영학회 2015 Global Fashion Management Conference Vol.2015 No.06
This study proposes the use of fashion as a tool of psychotherapy for individuals feeling social and psychological pressure due to society’s emphasis on appearances. The concept of fashion therapy was re-established, and theories (cognitive behavioral therapy, person-centered therapy, solution-focused brief therapy) founded on art therapy were introduced. Based on past research, this study developed a process for fashion therapy.
Yuri Cho,Jin Woo Choi,Hoon Kwon,Kun Yung Kim,Byung Chan Lee,Hee Ho Chu,Dong Hyeon Lee,Han Ah Lee,Gyoung Min Kim,Jung Suk Oh,Dongho Hyun,In Joon Lee,Hyunchul Rhim 대한간학회 2023 Clinical and Molecular Hepatology(대한간학회지) Vol.29 No.3
Transarterial chemoembolization (TACE) was introduced in 1977 with the administration of chemotherapeutic agent to gelatin sponge particles through the hepatic artery in patients with hepatocellular carcinoma (HCC) and was established as conventional TACE using Lipiodol in the 1980s. In the 2000s, drug-eluting beads were developed and applied clinically. Currently, TACE is a commonly used non-surgical treatment modality for patients with HCC who are unsuitable for curative treatment. Considering the vital role of TACE in the management of HCC, it is crucial to organize current knowledge and expert opinions regarding patient preparation, procedural techniques, and post-treatment care in TACE, which can enhance therapeutic efficacy and safety. A group of 12 experts in the fields of interventional radiology and hepatology, convened by the Research Committee of the Korean Liver Cancer Association (KLCA), has developed expert consensus-based practical recommendations in TACE. These recommendations have been endorsed by the Korean Society of Interventional Radiology and provide useful information and direction in performing TACE procedure as well as pre- and post- procedural patient care.
Lee, Yun Bin,Jung, Eun Uk,Kim, Bo Hyun,Lee, Jeong-Hoon,Cho, Hyeki,Ahn, Hongkeun,Choi, Won-Mook,Cho, Young Youn,Lee, Minjong,Yoo, Jeong-Ju,Cho, Yuri,Lee, Dong Hyeon,Cho, Eun Ju,Yu, Su Jong,Park, Sung J American Society for Microbiology 2015 Antimicrobial Agents and Chemotherapy Vol.59 No.2
<P>Tenofovir disoproxil fumarate (TDF) monotherapy is a therapeutic option for chronic hepatitis B (CHB) patients infected with hepatitis B virus (HBV) variants resistant to lamivudine (LAM). We evaluated the antiviral efficacy and safety of TDF alone compared to those of TDF plus LAM or telbivudine (LdT) combination in patients harboring HBV variants with genotypic resistance to LAM. This multicenter retrospective study included consecutive patients who had LAM-resistant HBV variants and were treated with TDF alone (monotherapy group) or TDF combined with LAM or LdT (combination therapy group) for at least 6 months. Inverse probability of treatment weighting (IPTW) for the entire cohort was applied to control for treatment selection bias. Overall, 153 patients (33 in the monotherapy group and 120 in the combination therapy group) were analyzed. The overall probability of achieving complete virologic suppression at month 12 was 91.6%: 88.6% in the monotherapy group and 92.6% in the combination therapy group. Combination therapy was not superior to monotherapy in viral suppression before and after IPTW (<I>P</I> = 0.562 and <I>P</I> = 0.194, respectively). Hepatitis B e antigen (HBeAg) loss, biochemical response, and virologic breakthrough did not differ between treatment groups. The probabilities of complete virologic suppression were comparable between treatment groups in the subsets according to HBeAg status and HBV DNA levels at baseline. No patient experienced any significant renal dysfunction during the treatment period. In conclusion, TDF monotherapy has antiviral efficacy comparable to that of TDF plus LAM or LdT combination therapy, with a favorable safety profile in CHB patients with LAM-resistant HBV variants.</P>
( Yuri Cho ),( Jeong Hoon Lee ),( Dong Hyeon Lee ),( Minjong Lee ),( Jeong Ju Yoo ),( Won Mook Choi ),( Young Youn Cho ),( Yun Bin Lee ),( Su Jong Yu ),( Yoon Jun Kim ),( Jung Hwan Yoon ),( Chung Yong 대한간학회 2013 춘·추계 학술대회 (KASL) Vol.2013 No.1
Background/aims: Entecavir (ETV) has an excellent efficacy in nucleos(t)ide analogue (NA)-naive chronic hepatitis B (CHB) patients, but data on the efficacy in patients who were exposed to lamivudine (LAM) but never developed LAM-resistance (LAM-R) are limited. In this study, we aimed to evaluate whether the probability of developing genotypic resistance to ETV in currently or previously LAM-exposed patients with/ without LAM-R is comparable to that in antiviral-naive patients. Methods: This study included 500 consecutive patients with CHB who started ETV monotherapy at a single tertiary hospital (Seoul, Korea) from 2007 to 2012. The patients were divided into three groups: NA-naive patients (group 1, n=142), patients who were ever exposed to LAM, but never developed LAM-R (group 2, n=233), and patients with LAM-R when starting ETV (group 3, n=125). The probabilities of developing ETV-resistance (ETV-R) were determined and compared by multivariate analysis. Results: Overall median treatment duration was 194.9 weeks (range, 41.4-337.0 weeks). The probabilities of virologic breakthrough were increased not only in group 3 (32.4%) but also in group 2 (10.3%), compared to group 1 (3.2%) (both P≤0.001). Genotypic ETV-R was more frequently developed in group 2 (odds ratio=17.3, P=0.006) as well as group 3 (odds ratio=57.4, P<0.001) than in group 1: the probabilities of developing ETVR in group 1, 2, and 3 were 0%, 33.7% and 49.8%, respectively, at week 192. Conclusions: This study indicates that ETV-R was developed more frequently in LAM-exposed patients, even though they never developed LAM-R, as compared to NA-naive patients. Therefore, LAM-exposed CHB patients, regardless of LAM-R, should be monitored more cautiously for the development of ETV-R during ETV monotherapy and further prospective studies on proper therapies in LAM-exposed patients are war ranted.
( Yuri Cho ),( Jeong Hoon Lee ),( Dong Hyeon Lee ),( Min Jong Lee ),( Jeong Ju Yoo ),( Won Mook Choi ),( Young Youn Cho ),( Yun Bin Lee ),( Eun Ju Cho ),( Su Jong Yu ),( Nam Joon Yi ),( Kwang Woong Le 대한간학회 2013 춘·추계 학술대회 (KASL) Vol.2013 No.1
Background/aims: Some patients with hepatocellular carcinoma (HCC) beyond the Milan criteria (MC) have favorable tumor biology, and that these patients would have low risk of tumor recurrence after living donor liver transplantation (LDLT). This study was designed to develop a model of tumor recurrence after LDLT for HCC beyond the MC, so as to select the best candidates for LDLT in HCC beyond the MC. Methods: Consecutive patients who had undergone LDLT beyond the MC at Seoul National University Hospital between September 2001 and January 2013 were analyzed. Demographic, clinical, and tumor characteristics were evaluated and a model to predict recurrence after LDLT (MoRAL score) was created. Results: A total of 104 patients were included. The median follow-up was 52.7 (range, 1.6-157.5) months. Their 5-year overall survival and cumulative recurrence rates were 70.4% and 41.8%, respectively. In multivariate analysis, independent pretransplant risk factors for HCC recurrence were serum AFP (OR=1.003, P=0.013) and PIVKA-II (OR=1.001, P=0.050) levels. AFP reflected maximal tumor size and PIVKA-II reflected tumor number and type (nodular or diffuse/infiltrative) (all P<0.001). Using Cox proportional hazards model, MoRAL score ( )was derived (median, 108.3; range 33.7-3928.3). The concordance statistic of MoRAL (0.836) was superior to CLIP score (0.772), TNM stage (0.600), JIS stage (0.601) and T classification (0.626). The tumor recurrence after LDLT was significantly related to mortality (OR=21.6, P<0.001). Conclusions: A new model to predict tumor recurrence of HCC patients beyond the MC after LDLT based on objective parameters provides refined prognostication (Figure 1). External validation is warranted.
( Yuri Cho ),( Jung Hwan Yoon ),( Dong Hyeon Lee ),( Yun Bin Lee ),( Eun Ju Cho ),( Jeong Hoon Lee ),( Su Jong Yu ),( Yoon Jun Kim ),( Hyo Suk Lee ),( Chung Yong Kim ) 대한간학회 2013 춘·추계 학술대회 (KASL) Vol.2013 No.1
Background: The crosstalk between tumor cells and their microenvironment plays a crucial role in the development, progression and metastasis of HCC. Hypoxia, a common feature of advanced hepatocellular carcinoma (HCC), has been known to modulate the development and evolution of the tumor microenvironment. However, the mechanism and functional impact of the tumor-stroma co-evolution in hypoxic HCC remains poorly understood. In this study, we investigated the effects of hypoxia on the tumor-stroma crosstalk in HCC. Methods: Human HCC cells (Huh-BAT and HepG2) were co 2) either in a normoxic or hypoxic condition. Cell growth, migration capacity and apoptosis were assessed using the MTS assay, wound healing assay and DAPI staining. Global gene expression profiling under chronic hypoxia was determined by microarray analysis. Results: Co-culturing HCC cells with HSCs in hypoxia significantly enhanced proliferation and migration of both cells as compared to normoxic condition. Co-culturing also decreased bile acid- or TRAIL-induced HCC cell apoptosis. Unsupervised genome-wide expression profiling showed that 1887 genes were differentially expressed in co-cultured HCC cells with HSCs and 503 genes in HSCs with HCC cells under hypoxia, including genes that encode cell cycle, signaling transduction, cell surface receptors and redox reaction. Hepatocyte?HSC cross-talk was bidirectional and resulted in the deregulation of functionally relevant gene profiles. Conclusions: These results indicate that the enhanced bidirectional cross-talk between HCC cells and activated HSCs is an important feature of HCC progression under hypoxia.